MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329497 | Name: Dotinurad
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dotinurad is a selective urate reabsorption inhibitor that targets URAT1 (urate transporter 1) in the renal proximal tubules. By inhibiting URAT1, Dotinurad reduces the reabsorption of uric acid, thereby increasing its excretion in urine and lowering serum uric acid levels. It is primarily used in the treatment of hyperuricemia associated with gout and other urate-related disorders.

Chemical Structure

Dotinurad
Dotinurad
CAS#1285572-51-1

Theoretical Analysis

MedKoo Cat#: 329497

Name: Dotinurad

CAS#: 1285572-51-1

Chemical Formula: C14H9Cl2NO4S

Exact Mass: 356.9629

Molecular Weight: 358.19

Elemental Analysis: C, 46.95; H, 2.53; Cl, 19.79; N, 3.91; O, 17.87; S, 8.95

Price and Availability

Size Price Availability Quantity
1mg USD 400.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Dotinurad; FYU-981; FYU 981; FYU981;
IUPAC/Chemical Name
(3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2H)-yl)methanone
InChi Key
VOFLAIHEELWYGO-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2
SMILES Code
ClC1=C(O)C(Cl)=CC(C(N2CS(C3=C2C=CC=C3)(=O)=O)=O)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 358.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kuriyama S. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):1-5. doi: 10.1007/s10157-019-01811-9. Epub 2019 Nov 21. Erratum in: Clin Exp Nephrol. 2020 Jan 22;: PMID: 31754883; PMCID: PMC7066308. 2: Ishikawa T, Takahashi T, Taniguchi T, Hosoya T. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406. doi: 10.1080/14656566.2021.1918102. Epub 2021 Apr 30. PMID: 33926357. 3: Omura K, Miyata K, Kobashi S, Ito A, Fushimi M, Uda J, Sasaki T, Iwanaga T, Ohashi T. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor. Drug Metab Pharmacokinet. 2020 Jun;35(3):313-320. doi: 10.1016/j.dmpk.2020.03.002. Epub 2020 Mar 9. PMID: 32327267. 4: Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):62-70. doi: 10.1007/s10157-020-01849-0. Epub 2020 Jan 24. PMID: 31980978; PMCID: PMC7066104. 5: Tanaka Y, Nagoshi T, Takahashi H, Oi Y, Yoshii A, Kimura H, Ito K, Kashiwagi Y, Tanaka TD, Yoshimura M. URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice. Mol Metab. 2022 Jan;55:101411. doi: 10.1016/j.molmet.2021.101411. Epub 2021 Dec 1. PMID: 34863940; PMCID: PMC8717577. 6: Iqbal A, Iqbal K, Farid E, Ishaque A, Hasanain M, Bin Arif T, Arshad Ali S, Rathore SS, Malik M. Efficacy and Safety of Dotinurad in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2021 Apr 12;13(4):e14428. doi: 10.7759/cureus.14428. PMID: 33996294; PMCID: PMC8114961. 7: Kumagai Y, Sakaki M, Furihata K, Ito T, Inoue K, Yoshida T, Matsumoto S, Furuno K, Hagino A. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):25-35. doi: 10.1007/s10157-019-01816-4. Epub 2019 Nov 23. PMID: 31760530; PMCID: PMC7066095. 8: Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, Chikamatsu N, Hagihara C, Hashiba M, Iwanaga T. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. J Pharmacol Exp Ther. 2019 Oct;371(1):162-170. doi: 10.1124/jpet.119.259341. Epub 2019 Aug 1. PMID: 31371478. 9: Nakatani H, Fushimi M, Sasaki T, Okui D, Ohashi T. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):8-16. doi: 10.1007/s10157-019-01836-0. Epub 2019 Dec 30. PMID: 31889230; PMCID: PMC7066278. 10: Lee YH, Song GG. Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Mar;60(3):159-166. doi: 10.5414/CP204097. PMID: 34779393. 11: Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T. Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity. ACS Med Chem Lett. 2020 Jul 15;11(10):2017-2023. doi: 10.1021/acsmedchemlett.0c00176. PMID: 33062187; PMCID: PMC7549256. 12: Motoki K, Igarashi T, Omura K, Nakatani H, Iwanaga T, Tamai I, Ohashi T. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers. Pharmacol Res Perspect. 2019 Nov 26;7(6):e00533. doi: 10.1002/prp2.533. PMID: 31788318; PMCID: PMC6880184. 13: Takahashi T, Beppu T, Hidaka Y, Hosoya T. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials. Clin Exp Hypertens. 2021 Nov 17;43(8):730-741. doi: 10.1080/10641963.2021.1950752. Epub 2021 Aug 23. PMID: 34425059. 14: Li YJ, Chen LR, Yang ZL, Wang P, Jiang FF, Guo Y, Qian K, Yang M, Yin SJ, He GH. Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis. Clin Rheumatol. 2023 Jan;42(1):215-224. doi: 10.1007/s10067-022-06356-z. Epub 2022 Aug 29. PMID: 36036279. 15: Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):44-52. doi: 10.1007/s10157-019-01802-w. Epub 2019 Nov 21. PMID: 31754882; PMCID: PMC7066315. 16: Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double- blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):53-61. doi: 10.1007/s10157-019-01818-2. Epub 2019 Dec 3. PMID: 31792640; PMCID: PMC7066091. 17: Fujita K, Zhu Q, Arakawa H, Shirasaka Y, Tamai I. Potentiation of the Uricosuric Effect of Dotinurad by Trans-Inhibition of the Uric Acid Reabsorptive Transporter URAT1. Drug Metab Dispos. 2023 Aug 29:DMD- AR-2023-001412. doi: 10.1124/dmd.123.001412. Epub ahead of print. PMID: 37643882. 18: Taniguchi T, Ashizawa N. [Pharmacological properties and clinical efficacy of dotinurad (URECE® tablets), a novel hypouricemic agent]. Nihon Yakurigaku Zasshi. 2020;155(6):426-434. Japanese. doi: 10.1254/fpj.20047. PMID: 33132262. 19: Omura K, Motoki K, Kobashi S, Miyata K, Yamano K, Iwanaga T. Identification of Human UDP-Glucuronosyltransferase and Sulfotransferase as Responsible for the Metabolism of Dotinurad, a Novel Selective Urate Reabsorption Inhibitor. Drug Metab Dispos. 2021 Nov;49(11):1016-1024. doi: 10.1124/dmd.120.000251. Epub 2021 Aug 11. PMID: 34380635. 20: Taniguchi T, Omura K, Motoki K, Sakai M, Chikamatsu N, Ashizawa N, Takada T, Iwanaga T. Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2. Sci Rep. 2021 Mar 31;11(1):7232. doi: 10.1038/s41598-021-86662-9. PMID: 33790363; PMCID: PMC8012596.